Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7337877 | PMC |
| http://dx.doi.org/10.1093/jac/dkaa253 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The effectiveness of nirmatrelvir/ritonavir regimen in hospitalized renal transplant patients with prolonged COVID-19 infection: a multicenter clinical experience.
Ren Fail
December 2024
Organ Transplant Center, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
Objectives: Effectiveness of nirmatrelvir/ritonavir (NR) in kidney transplant recipients (KTRs) infected COVID-19 for more than 5 days has not been evaluated.
Methods: In this multicenter retrospective study, 85 KTRs with COVID-19 were enrolled, including 50 moderate, 21 severe, and 14 critical patients.
Results: The median time from onset to starting NR treatment was 14 (IQR, 11-19) days.
Mitochondrial DNA mutations in HIV-exposed uninfected infants following the cessation of triple antiretroviral drugs.
J Antimicrob Chemother
February 2024
National Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China.
Objectives: Mitochondrial mutations in HIV-exposed uninfected (HEU) infants after cessation of ART are rarely studied. We analysed a group of HEU newborns born to mothers with late HIV diagnosis who received three doses of ART immediately after birth. We observed mitochondrial DNA (mtDNA) mutations at different times of withdrawal.
View Article and Find Full Text PDFLong-term (180-Day) Outcomes in Critically Ill Patients With COVID-19 in the REMAP-CAP Randomized Clinical Trial.
JAMA
January 2023
Peter Munk Cardiac Centre at University Health Network, Toronto, Ontario, Canada.
Importance: The longer-term effects of therapies for the treatment of critically ill patients with COVID-19 are unknown.
Objective: To determine the effect of multiple interventions for critically ill adults with COVID-19 on longer-term outcomes.
Design, Setting, And Participants: Prespecified secondary analysis of an ongoing adaptive platform trial (REMAP-CAP) testing interventions within multiple therapeutic domains in which 4869 critically ill adult patients with COVID-19 were enrolled between March 9, 2020, and June 22, 2021, from 197 sites in 14 countries.
QTc interval prolongation in patients infected with SARS-CoV-2 and treated with antiviral drugs.
An Pediatr (Engl Ed)
March 2022
Servicio de Cardiología Pediátrica, Hospital Universitario Vall d'Hebron, Barcelona, Spain; Paediatric Cardiology Department, Royal Brompton and Harefield NHS Foundation Trust, Londres, UK. Electronic address:
Introduction: Many antiviral agents, such as hydroxychloroquine, have been used to treat COVID-19, without being broadly accepted. QTc prolongation is a worrisome adverse effect, scarcely studied in pediatrics.
Patients And Methods: Paediatric patients affected from COVID-19 who received antivirals were matched (1:2) with controls not infected nor exposed.
Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial.
Lancet Infect Dis
February 2022
Université de Paris, IAME, INSERM, Paris, France; Département d'Épidémiologie, Biostatistique et Recherche Clinique, Hôpital Bichat, AP-HP, Paris, France.
Background: The antiviral efficacy of remdesivir against SARS-CoV-2 is still controversial. We aimed to evaluate the clinical efficacy of remdesivir plus standard of care compared with standard of care alone in patients admitted to hospital with COVID-19, with indication of oxygen or ventilator support.
Methods: DisCoVeRy was a phase 3, open-label, adaptive, multicentre, randomised, controlled trial conducted in 48 sites in Europe (France, Belgium, Austria, Portugal, Luxembourg).
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!